ArticleNature medicine2022

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.

Joseph P Casazza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.